semaglutide and liver disease Semaglutide's Efficacy in Phase 3 MASH Trial Semaglutide adds liver disease improvements

In laboratory animals, the forced overexpression of the TKT gene promotes the development of MAFLD as well as the advancement of MAFLD to the more severe state referred to as metabolic dysfunction-associated steatohepatitis (MASH)

Focus on what you can do, when you can do it, and let consistency build gradually

Urva, et al., LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept, 2022, Cell Metabolism 34, 12341247

Following a 1-week acclimatization period, the mice were randomly assigned to four groups (n = 8): Control, DSS, DSS + 5-ASA, and DSS + GHK-Cu